Turpaz 2025: The Operating Engine Strengthened, but Purchase Liabilities Are the Real Test

Company Overview

Turpaz no longer looks like a local niche producer that went shopping. By the end of 2025 it had become a global flavors, fragrances, and specialty ingredients platform, with $275.1 million of revenue, 26 production sites, more than 4,300 customers, 1,053 employees, and 87% of sales generated outside Israel. What is working right now is the operating engine itself: group organic growth reached 13.3%, gross margin improved to 40.0%, and operating cash flow almost doubled to $40.7 million.

What a superficial reading may miss is that this is not just another acquisition-heavy year. Organic growth reached 9.0% in Taste, 8.6% in Fragrance, and 65.6% in Specialty Fine Ingredients. On top of that, a major customer that accounted for 10% or more of reported revenue in 2024 fell below that threshold in 2025. In other words, Turpaz is not only buying growth, it is also broadening its revenue base.

But the bottleneck has changed. Bank leverage on its own is no longer the main issue, since net debt fell to $36.2 million and net debt to EBITDA on a pro forma basis stood at just 0.5. The pressure has shifted to another layer: purchase liabilities stood at $146.9 million on the balance sheet at year-end 2025, while put options and contingent consideration totaled $139.7 million. At the same time, net intangible assets climbed to $332.5 million, above the company’s $293.4 million equity base. That is the core issue. Turpaz has already shown that it can buy and integrate assets. The next step is proving that the earnings from those assets will actually turn into accessible cash rather than staying trapped at the level of goodwill, formulas, and future obligations.

This matters now because two early 2026 moves sharpen the thesis. In February, the Put/Call mechanism at Attractive Scent was canceled and Turpaz immediately bought the remaining 31.4% for €20.1 million. In December, the board also approved a separation of the Chair and CEO roles, so that from January 2026 Karen Cohen Khazon remained CEO and director, while Dr. Israel Leshem became Chair. In plain terms, 2025 closed one phase of platform building, and 2026 opens as a test of platform monetization.

This is what the economic map looks like:

Turpaz still looks like a Taste company by revenue weight, with Taste accounting for 70.7% of sales, but the higher-quality economics sit in Fragrance. Europe alone generated $162.2 million of revenue, more than half the group total, and revenue per employee stands at roughly $261,000. This is no longer a domestic producer with export activity. It is an international manufacturing, R&D, and commercial network.

Events And Triggers

Six transactions in one year, but not all of them do the same thing

First trigger: 2025 was an intense deal year. From the start of the year through the report date, Turpaz completed six transactions in England, Belgium, Poland, India, France, and South Africa. But not every deal has the same meaning. Doucy in Belgium and Nicola-J in South Africa expand the Taste engine. Carotex in Poland and Attractive Scent in France strengthen both Taste and Fragrance, each in a different pocket of the market. Aastrid in India is a 45% investment accounted for under the equity method, so it adds strategic optionality more than immediate consolidated sales.

Second trigger: Attractive Scent is the deal that changes the story, not just the headline. In July 2025 Turpaz bought 68.6% of the French company for €27.4 million, and the acquired business contributed $11.2 million of revenue and $1.35 million of net profit in the second half of the year. In February 2026 the Put/Call structure was canceled and Turpaz bought the remaining 31.4% for €20.1 million, including €7.3 million in shares, €0.7 million in immediate cash, and €12.1 million of deferred cash due in February 2029. This is a two-sided move. It creates full alignment inside the Fragrance division and simplifies the structure, but it also turns an optional future mechanism into a concrete payment schedule.

Third trigger: in August 2025 the company completed a private placement of 7.105 million shares and raised $97.2 million net. That clearly helped the balance sheet, lifting equity to $293.4 million and the equity ratio to 41.1%. But it also shows that the platform is not funding the current acquisition pace solely through operating cash flow.

Fourth trigger: the Chair and CEO split that took effect in January 2026 is not cosmetic. After years in which Karen Cohen Khazon held both roles, the company moved to fit governance to a much larger and more complex platform. That looks like a natural maturity step, but it also raises the bar on execution. The company still explicitly identifies material dependence on Ms. Cohen Khazon.

Fifth trigger: in March 2026 the board approved a $6.8 million dividend. That is a signal of confidence, but not a free one. A company with stronger operating cash flow, higher cash balances, and better equity metrics can afford to distribute capital. A company with $146.9 million of purchase liabilities and $139.7 million of put options and contingent consideration also needs to show why that distribution does not come at the expense of future flexibility.

Efficiency, Profitability And Competition

The core insight is that the improvement in profitability is real, but it does not all sit at the same layer. Part of it is operational. Part of it comes from scale. Part of it still runs through acquisition accounting.

What actually drove the margin improvement

Group revenue rose 45.6% to $275.1 million. That is strong in itself, but what matters more is that gross profit rose faster, by 49.4%, and gross margin improved to 40.0% from 39.0%. Operating profit increased to $43.4 million, and a 15.8% operating margin versus 14.7% in 2024 means scale finally started to work.

Still, not every cost line improved in the same way. R&D moved up to 4.0% of sales from 3.7%, and selling and marketing rose to 9.6% from 8.6%, partly because of acquired businesses and the amortization burden attached to them. General and administrative expense, however, improved as a share of sales, falling to 10.7% from 11.7%. So this is not a pure cost-cutting story. It is a story of better gross profitability, synergies, and scale absorbing a heavier operating structure.

The gap between reported earnings and adjusted earnings is too large to ignore. Reported net profit came in at $22.7 million, while Non-GAAP net profit reached $36.4 million. The $13.7 million gap mainly reflects $8.9 million of intangible amortization and share-based compensation, plus $6.0 million of financing expense related to put options, net of tax. This is not just optics. It is the direct cost of the growth model. If the goal is to assess operating earning power, looking at the adjusted number has value. If the goal is to understand what is left for shareholders after the acquisition strategy, the reported number is the one that matters.

The segments that are carrying the year

Taste remains the group’s anchor, with $194.7 million of revenue and $37.6 million of operating profit. It is the scale engine, and in 2025 it delivered 9.0% organic growth while also improving margin to 19.3%. In quality terms, that matters because the segment also looks less concentrated than before.

Fragrance is the highest-quality activity in the group. Revenue rose to $49.4 million, operating profit to $12.8 million, and margin held at 26.0% despite a busy acquisition year. That matters because it shows that the French and Polish additions have not diluted quality. On the contrary, Attractive Scent in Grasse suggests Turpaz is deliberately shifting part of its center of gravity toward higher value-added fragrance niches.

Specialty Fine Ingredients is where investors need to be more careful. Revenue jumped 68.1%, and management highlights a mix shift toward aroma chemicals and citrus products for the flavors and fragrances industries, alongside a return of customers to Kimyda. That all sounds encouraging. But operating margin still fell to 11.8% from 16.5%. The company explains that part of the gap reflects state compensation of $2.8 million in 2024 versus $1.3 million in 2025. So the growth looks real, but the profitability base is still not fully clean.

Where the moat really sits

Turpaz’s moat is not a consumer brand. It is the combination of formulation know-how, customer customization, regulatory capability, service, and speed. The group has 133 R&D employees, 118 sales and marketing employees, 26 R&D and quality labs, and thousands of raw materials sourced from hundreds of suppliers. Management explicitly says there is no material dependency on any single customer or supplier in Taste and Fragrance.

In practice, this is an industrial solutions business. Customers do not easily switch flavor or fragrance suppliers because formulas are embedded in the finished product, in the customer’s quality process, and in local regulatory requirements. That is a real moat. The trade-off is that people matter a great deal in this model, and the company itself still points to material dependence on its CEO.

Cash Flow, Debt And Capital Structure

The key point is that anyone who looks only at net debt will miss the real structure of risk. Turpaz needs to be read in two layers, the banking layer and the business-acquisition layer.

The banking layer looks comfortable

On the first layer, the picture is good. The group ended 2025 with $143.1 million of cash and cash equivalents, up from $25.9 million a year earlier. Total bank and other borrowing stood at $179.3 million, which leaves net debt at just $36.2 million. Net debt to EBITDA stood at 0.5, far below the 3.5 covenant ceiling. Equity reached $293.4 million and represented 41.1% of the balance sheet, above both the absolute $80 million minimum and the 20% ratio threshold.

The parent level also looks more liquid than the consolidated number alone may imply. In the company-only statements, cash and cash equivalents stood at $108.4 million. That matters because it suggests a meaningful share of liquidity is not buried too deep in subsidiaries.

The company also had a non-binding credit line of roughly $141 million, subject to specific approvals. Average weighted interest on bank borrowing was 4.36%, and a 0.5% move in rates translates into roughly $0.83 million of pre-tax earnings sensitivity. That is a real exposure, but it is not what defines the thesis right now.

The business-acquisition layer is much heavier

This is where the story gets more complex. Purchase liabilities stood at $12.4 million short term and $134.5 million long term, or $146.9 million in total, versus only $76.3 million at the end of 2024. In the contractual maturity table, the figure rises to $171.1 million, of which $158.8 million sits in the one-to-five-year bucket. That is a real obligation, even if it does not all show up as conventional bank debt.

There is another layer on top of that. Put options and contingent consideration totaled $139.7 million, up from $74.8 million in 2024. The company explicitly states that these balances are based on future EBITDA assumptions for the acquired businesses, and that a 5% change in EBITDA shifts the valuation by about $3.2 million. This is leverage of a different kind, less bank-driven and more dependent on integration, performance, and valuation assumptions.

Net intangible assets also rose to $332.5 million, including $228.4 million of goodwill. That means a large part of the balance sheet now depends on Turpaz’s ability to continue extracting value from acquired businesses. As long as that works, the model looks strong. If one of the larger acquired units starts to disappoint, the accounting cushion is less comfortable than the low net debt ratio alone suggests.

Cash framing, two pictures and they are not the same

normalized / maintenance cash generation: after $40.7 million of operating cash flow, $5.3 million of total lease-related cash outflow, and $12.5 million of reported CAPEX, the business generated about $22.9 million before acquisitions, debt repayments, and other capital uses. That is a solid number, and it helps explain why management feels comfortable talking about dividends and continued growth.

all-in cash flexibility: once the full cash uses are included, the conclusion changes. Investing cash flow was negative $83.3 million, including $60.3 million for consolidated acquisitions and another $10.1 million for equity-method investments. At the same time, financing cash flow was positive $150.3 million, including $86.1 million of new long-term loans and $97.2 million of net equity issuance. In other words, the core business is producing cash, but the acquisition platform is still being funded externally.

That is not automatically a negative. Turpaz chose to finance an unusually active deal year with equity and debt while its capital structure was still strong. But it is exactly why the next test is not another deal announcement. It is the quality of the integration of the deals that have already been done.

Outlook

Four findings to keep in mind before 2026:

• Turpaz’s organic engine is real, not just a function of acquisition accounting.
• Fragrance has been strategically upgraded, but it also now carries a more explicit capital commitment.
• Specialty Fine Ingredients has returned to growth, but still has to prove margin quality.
• The main risk has shifted from bank leverage to capital discipline, integration quality, and acquisition follow-through.

What management is signaling without saying it directly

Management is still speaking in the same strategic voice: double revenue every four years, keep acquiring, focus on smaller local companies in North America, Europe, Asia, and Africa, and expand the aroma chemicals and citrus activity through cooperation in India, China, and Romania. That means management is not going into defensive mode. It still sees 2026 as a continuation year.

But underneath that optimistic language there is a more important signal. The report repeatedly stresses synergies, cross-selling, global procurement, shared development, and further extraction of value from acquisitions already completed. That is management language for a transition from expansion to digestion. If 2025 was a leap year, 2026 looks like a proof year. Not a fresh breakout year, and not a reset year. A proof year for whether the platform can create depth, not just breadth.

What must happen over the next 2-4 quarters

The first thing the market will measure is earnings quality in Fragrance. Attractive Scent only contributed from July 2025, and the move to full ownership only happened in February 2026. If the division can keep margins near current levels while broadening its footprint, that will support the case that this was more than a strategic headline deal.

The second thing is Specialty Fine Ingredients. Management describes mix improvement, new product launches, and customer returns to Kimyda. That all sounds encouraging. But the bottom line still shows an 11.8% full-year margin and a 9.8% fourth-quarter margin. The market will want to see whether the promised improvement in coming quarters actually appears.

The third thing is the pace at which the liability layer opens and closes. It is not enough for Turpaz to report more EBITDA. It has to show that this EBITDA turns into cash that can service purchase liabilities, lease obligations, debt repayments, and disciplined capital returns.

The fourth thing is the pace of new deals. Turpaz says it is reviewing additional acquisitions. If it keeps buying at the same speed before investors get evidence from the 2025 deal batch, that may create friction. Not because the company cannot buy, but because the market will want proof of digestion first.

Short Interest Read

The short-interest data matters precisely because it is not extreme. Short float peaked at 2.19% in mid-February 2026 with an SIR of 7.51, then fell to 0.78% and 1.29 by late March. For context, the sector average stands at 0.11% short float and 0.387 days to cover.

That means there was a brief period of elevated skepticism around the reporting cycle and the deal stack, but it eased quickly. This is not a classic short story. The market is not setting up for a squeeze, and it is not pricing in collapse. It is mostly waiting for confirmation that 2025 profitability and liquidity really represent a new stage rather than a well-funded transition year.

Risks

First risk, integration and purchase liabilities

This is the biggest risk because it sits at the center of the thesis. Purchase liabilities, minority put options, and contingent consideration are now part of the core story. If one of the acquired businesses misses the EBITDA assumptions embedded in those structures, Turpaz can face either an operating gap, a cash-flow problem, or both.

Second risk, currency and rates

A 10% move in the US dollar against the rest of the currency basket translates into roughly $26.7 million of pre-tax earnings sensitivity. That is not background noise. Turpaz sells in several currencies and operates across the euro, US dollar, shekel, rand, and zloty. Management argues that part of the exposure is naturally balanced because many raw materials are bought in dollars and local operating costs sit in local currencies, but this is still a company whose reported numbers can look very different when exchange rates move.

Third risk, production sites and regulation

The group is spread across 26 production sites, but it still has meaningful exposure to key sites. At Kimyda in Nir Yitzhak, the company invested about $2.9 million in an emissions treatment system, yet as of the report date it had still not been installed because of the war and the site’s proximity to Gaza. Installation is expected in the first half of 2026. That is exactly the kind of external choke point the market may miss on a quick first read.

Fourth risk, governance and management concentration

The Chair and CEO split is a positive step, but it does not eliminate management concentration. The company still explicitly identifies material dependence on Karen Cohen Khazon, and several senior roles remain tied to the controlling shareholder’s family. That does not automatically mean weak governance, but it does mean the market will continue to put a high weight on the execution capacity of the existing management circle.

Conclusions

Turpaz enters 2026 from a position of real operating strength. Taste and Fragrance both show that the platform can grow organically, and the banking balance sheet is nowhere near pressure. But the market reading will no longer be determined mainly by whether the company can close another deal. It will be determined by whether Turpaz can prove that its growing stack of purchase liabilities, minority options, and intangible assets is creating accessible value for shareholders.

Current thesis: Turpaz has already shown that it can buy growth, and 2026 will test whether it can digest that growth without adding obligations faster than cash generation.

What changed: the story has shifted from proving demand and early integration to proving capital discipline. Bank leverage is no longer the main concern. The acquisition-obligation layer is.

Counter thesis: the market may be overstating the liability concern, because the company holds a large cash cushion, has strong core margins, retains financing access, and has already demonstrated credible acquisition integration capabilities.

What may change the market’s interpretation: two things, evidence that Fragrance can sustain current earnings quality, and visible improvement in Specialty Fine Ingredients margins without relying on compensation or base effects.

Why it matters: Turpaz is trying to prove that an Israeli-built global flavors and fragrances platform can move from platform construction to real cash-based value creation for common shareholders.

What must happen next: over the next 2-4 quarters the company needs to show Attractive Scent integration, cleaner Specialty Fine Ingredients profitability, and disciplined use of existing liquidity and debt capacity.